23:27 , Aug 17, 2017 |  BC Innovations  |  Targets & Mechanisms

GRP-THINK AT THE BBB

Biogen Inc. has discovered antibodies in patients with a rare CNS autoimmune disease that could provide a new way to deliver mAbs across the blood-brain barrier, an application with wide-reaching ramifications for neurologic drug development. The...
22:11 , Jul 3, 2017 |  BC Extra  |  Company News

Acer finds public path via Opexa merger

Rare disease company Acer Therapeutics Inc. (Cambridge, Mass.) will merge with gene therapy company Opexa Therapeutics Inc. (NASDAQ:OPXA) to form a publicly traded company that will retain Acer's name. The combined company intends to submit...
12:08 , May 24, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Autoimmune Cell culture studies suggest inhibiting FCGR could help treat neuromyelitis optica (NMO). In primary mouse astrocytes treated with serum from NMO patients, astrocyte knockout of FCGR decreased internalization of the NMO marker AQP4 from...
07:00 , Sep 18, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Aquaporin-4 (AQP4); corticotropin-releasing factor 1 (CRF1); corticotropin-releasing factor receptor 1 (CRHR1; CRFR1) Rat studies suggest...
07:00 , Apr 11, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

This week in techniques Approach Summary Licensing status Publication and contact information Assays & screens Panel of peptoid ligands of aquaporin-4 (AQP4) autoantibodies for diagnosing neuromyelitis optica (NMO) ...
08:00 , Dec 6, 2012 |  BC Innovations  |  Tools & Techniques

Micromanaging tolerance

Researchers at Northwestern University and the Myelin Repair Foundation have simplified an autologous cell-based strategy for promoting antigen-specific tolerance by replacing splenic leukocytes with synthetic microparticles as the antigen carrier.1 The groups are planning to...
08:00 , Feb 14, 2000 |  BC Week In Review  |  Company News

University of California other research news

UCSF researchers and colleagues published in Nature Medicine that mice deficient in AQP4 had improved outcome and survival in models of brain edema (swelling) and stroke. They concluded that AQP4 plays a role in water...
08:00 , Jan 31, 2000 |  BC Extra  |  Clinical News

U.C. cerebral disorder target

UCSF researchers and colleagues published in Nature Medicine that mice deficient in AQP4 had improved outcome and survival in models of brain edema (swelling) and stroke. They concluded that AQP4 plays a role in...